RHHBY Roche Holdings AG ADR

$54.45
$0.35
(0.64%)
Today
Closed $54.45
$0.0969
(0.18%)
After Hours
46

Neutral Sentiment

How do you feel about RHHBY?

Loading...
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Zacks
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Zacks
Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
RHHBY's enicepatide cut HbA1c and body weight in a phase II study, strengthening its obesity ambitions as it advances the drug into phase III.
Zacks
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Zacks
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
Zacks
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Zacks
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
Zacks
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Zacks
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
Zacks